Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kamada has announced that the Israeli Ministry of Health elected the company to be the exclusive developer and manufacturer of snakebite antiserums in Israel.
Subscribe to our email newsletter
The Israeli Ministry of Health will finance the entire project, including the development, planning and production of the snakebite antiserum and the establishment of an antiserum manufacturing facility.
The estimated cost is $5 million, which will be paid in installments to the company throughout the duration of the agreement. The project is subject to the signature of a final agreement and is estimated to be completed within two years. After the completion of the project, Kamada will manufacture the antiserum for the Ministry of Health on an ongoing basis.
Prior to signing a final agreement, Kamada will begin the first stages of development against an advance payment that will be transferred to the company by the Ministry of Health.